AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA

Representações que afirmem ou sugiram a existência de uma relação entre o consumo de determinado alimento ou seu constituinte e a saúde podem ser veiculadas quando forem atendidas as diretrizes básicas para comprovação de propriedades funcionais ou de saúde estabelecidas na Resolução n. 18, de 30 de abril de 1999 (/legislacao#/visualizar/26339). Além da segurança do alimento, essas diretrizes visam que as alegações sejam comprovadas cientificamente e não induzam o consumidor ao engano. As alegações podem descrever o papel fisiológico do nutriente ou não nutriente no crescimento, desenvolvimento e nas funções normais do organismo. As alegações podem, ainda, fazer referência à manutenção geral da saúde e à redução do risco de doenças.

[1]  V. Wahn,et al.  The use of intravenous immunoglobulins in symptomatic HIV infection , 1994, The clinical investigator.

[2]  C. Mueller-Eckhardt,et al.  High-dose IgG for post-transfusion purpura-revisited , 1988, Blut.

[3]  L. Haines,et al.  Intravenous immunoglobulin for the treatment of Kawasaki disease in children. , 2003, The Cochrane database of systematic reviews.

[4]  P. Sørensen.  Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials , 2003, Neurological Sciences.

[5]  F. Simeone,et al.  Treatment of toxic epidermal necrolysis with intravenous immunoglobulin. , 2003, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society.

[6]  H. Kroll,et al.  European collaborative study of the antenatal management of feto‐maternal alloimmune thrombocytopenia , 2003, British journal of haematology.

[7]  M. Blanca,et al.  Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  L. Mouthon,et al.  Les indications thrapeutiques des immunoglobulines intraveineuses , 2003 .

[9]  H. Tan,et al.  Treatment of toxic epidermal necrolysis in AIDS with intravenous immunoglobulins , 2003, Clinical and experimental dermatology.

[10]  I. Bruce,et al.  Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  P. Bordigoni,et al.  Successful treatment of chronic parvovirus B19 infection by high-dose immunoglobulin. , 2003, Clinical nephrology.

[12]  S. Chanalet,et al.  [Intravenous immunoglobulins for relapsing-remitting multiple sclerosis after failure of treatment with other immuno-modulators]. , 2003, Revue neurologique.

[13]  R. Kirsner,et al.  Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. , 2003, Archives of dermatology.

[14]  J. Roujeau,et al.  Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. , 2003, Archives of dermatology.

[15]  R. S. Padilla,et al.  Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. , 2003, Archives of dermatology.

[16]  J. Saffle,et al.  Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. , 2002, Journal of the American Academy of Dermatology.

[17]  A. Ziman,et al.  A second case of post‐transfusion purpura caused by HPA‐5a antibodies: successful treatment with intravenous immunoglobulin , 2002, Vox sanguinis.

[18]  T. Maisonobe,et al.  Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. , 2002, Arthritis and rheumatism.

[19]  S. Chevret,et al.  Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial , 2002, The Lancet.

[20]  I. Khouri,et al.  Immune Thrombocytopenic Purpura , 2018 .

[21]  R. Castelli,et al.  Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate. , 2002, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.

[22]  S. Vorstrup,et al.  Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. , 2001, Artificial organs.

[23]  G. Comi,et al.  Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy , 2001, Annals of neurology.

[24]  V. Meininger,et al.  Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. , 2001, Brain : a journal of neurology.

[25]  D. Adu,et al.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. , 2000, QJM : monthly journal of the Association of Physicians.

[26]  M. Kazatchkine,et al.  Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy , 2000, Ocular immunology and inflammation.

[27]  Teramo,et al.  Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia , 1999, Transfusion medicine.

[28]  T. Chuhjo,et al.  Successful treatment of persistent erythroid aplasia caused by parvovirus B19 infection in a patient with common variable immunodeficiency with low‐dose immunoglobulin , 1999, American journal of hematology.

[29]  J. Tschopp,et al.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. , 1998, Science.

[30]  H. Renz,et al.  A case of Crohn's disease with increased CD8 T-cell activation and remission during therapy with intravenous immunoglobulins. , 1998, Scandinavian journal of gastroenterology.

[31]  S. Chevret,et al.  Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravis , 1997 .

[32]  C. V. Jensen,et al.  A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results , 1997, Multiple sclerosis.

[33]  G. Nahler,et al.  Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study , 1997, Multiple sclerosis.

[34]  C. Bolton,et al.  Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. , 1996, Brain : a journal of neurology.

[35]  J. George,et al.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.

[36]  H. Deeg,et al.  A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. , 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  V. Bril,et al.  Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome , 1996, Neurology.

[38]  R. Berkowitz,et al.  Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. , 1996, American journal of obstetrics and gynecology.

[39]  W. Shearer,et al.  A CONTROLLED TRIAL OF INTRAVENOUS IMMUNE GLOBULIN FOR THE PREVENTION OF SERIOUS BACTERIAL INFECTIONS IN CHILDREN RECEIVING ZIDOVUDINE FOR ADVANCED HUMAN IMMUNODEFICIENCY VIRUS INFECTION , 1995, Pediatrics.

[40]  G. Comi,et al.  Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[41]  P. Yap.  Does intravenous immune globulin have a role in HIV-infected patients? , 1994, Clinical and experimental immunology.

[42]  B. Wechsler,et al.  Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. , 1994, The Journal of rheumatology.

[43]  N. Zosmer,et al.  Direct fetal administration of immunoglobulins: another disappointing therapy in alloimmune thrombocytopenia. , 1994, Fetal diagnosis and therapy.

[44]  J. Dambrosia,et al.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. , 1993, The New England journal of medicine.

[45]  M. Gent,et al.  A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. , 1993, The Journal of pediatrics.

[46]  F. Jennekens,et al.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[47]  D. Jayne,et al.  Pooled intravenous immunoglobulin in the management of systemic vasculitis. , 1993, Advances in experimental medicine and biology.

[48]  P. Schmitz,et al.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. , 1992, The New England journal of medicine.

[49]  M Takahashi,et al.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. , 1991, The New England journal of medicine.

[50]  K. Sullivan,et al.  Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. , 1990, The New England journal of medicine.

[51]  P. Brown,et al.  A simple and effective method for inactivating virus infectivity in formalin‐fixed tissue samples from patients with Creutzfeldt‐Jakob disease , 1990, Neurology.

[52]  J. Bussel,et al.  Isolated thrombocytopenia in patients infected with HIV: Treatment with intravenous gammaglobulin , 1988, American journal of hematology.

[53]  G. Gaedicke,et al.  [Treatment of Crohn disease with intravenous immunoglobulin]. , 1988, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde.

[54]  J. Matías‐Guiu,et al.  High-dose intravenous immunoglobulin in the management of myasthenia gravis. , 1987, Archives of internal medicine.

[55]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[56]  G. Gaedicke,et al.  INTRAVENOUS IMMUNOGLOBULIN VERSUS ORAL CORTICOSTEROIDS IN ACUTE IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1985, The Lancet.

[57]  A. Hirt,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1981, The Lancet.